Heidelberg Pharma AG (HPHA) Stock Statistics & Valuation Metrics

Heidelberg Pharma AG has a market cap or net worth of CHF111.24M. The enterprise value is $152.89.

Heidelberg Pharma AG has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Heidelberg Pharma AG’s return on equity (ROE) is 3.87 and return on invested capital (ROIC) is -175.53%.

The current PE Ratio of Heidelberg Pharma AG is ―. Heidelberg Pharma AG’s PEG ratio is -0.03.

In the last 12 months, Heidelberg Pharma AG had revenue of 1.46M and earned -42.28M in profits. Earnings per share was -0.91.

In the last 12 months, operating cash flow was -24.80M and capital expenditures -62.89K, giving a free cash flow of -24.86M billion.

Heidelberg Pharma AG pays an annual dividend of ―, resulting in a dividend yield of ―

Heidelberg Pharma AG upcoming earnings date is Jul 15, 2026, Before Open (Confirmed).

Heidelberg Pharma AG as a current ratio of 2.53, with Debt / Equity ratio of -0.32%

In the past 12 months, Heidelberg Pharma AG has paid 1.05M in taxes.

Heidelberg Pharma AG EV to EBITDA ratio is -2.70, with an EV/FCF ratio of -3.80.

Heidelberg Pharma AG has CHF24.93M in cash and marketable securities with CHF45.98K in debt, giving a net cash position of CHF24.88M billion.

Gross margin is 85.90%, with operating margin of -3255.36%, and net profit margin of -2901.15%.

The average price target for Heidelberg Pharma AG is ―, which is 11.43% higher than the current price. The consensus rating is ―